Copyright
©The Author(s) 2017.
World J Transplant. Feb 24, 2017; 7(1): 57-63
Published online Feb 24, 2017. doi: 10.5500/wjt.v7.i1.57
Published online Feb 24, 2017. doi: 10.5500/wjt.v7.i1.57
Characteristics | n = 11 |
Age in years-mean (variation) | 41.3 (19-61) |
Female gender | 7 (63.3) |
Transplant time in years - mean (variation) | 3.6 (1 mo-9 yr) |
Deceased donor | 9 (82.0) |
Thymoglobulin induction | 4 (36.6) |
Immunosuppressive regimens | |
PRED + TAC + MMF | 4 (36.3) |
PRED + CYA + AZA | 2 (18.1) |
PRED + TAC + MPS | 2 (18.1) |
TAC + MMF | 1 (9.0) |
PRED + AZA + SRL | 1 (9.0) |
CYA | 1 (9.0) |
Rejection before dengue | 3 (27.2) |
Clinical findings | |
Fever | 11 (100.0) |
Myalgia | 10 (91.0) |
Headache | 6 (54.5) |
Abdominal pain | 3 (27.2) |
Bleedings | 3 (27.2) |
Nauseas and vomiting | 2 (18.1) |
Postural hypotension | 2 (18.1) |
Pleural effusions | 2 (18.1) |
Laboratory outcomes | |
Thrombocytopenia | 9 (81.8) |
Severe Thrombocytopenia (< 50000/mm3) | 4 (36.6) |
Leucopenia | 4 (36.6) |
Hemoconcentration | 4 (36.6) |
Transaminases increase (AST;ALT) | 7 (63.6) |
AST value, mean (variation) UI/L | 130 (17-360) |
ALT value, mean (variation) UI/L | 100 (14-230) |
Hospitalization | 9 (81.8) |
Hospitalization time in d, mean(variation) | 14.2 (3-45) |
Classification of dengue cases | |
Classical dengue | 9 (81.8) |
DHF | 2 (18.1) |
Dengue with complication | 0 |
Characteristics | n = 11 |
Resolution of symptoms | 11 (100) |
Death | 0 |
Time for resolution of symptoms in d, mean (variation) | 9 (2-20) |
Creatinine before dengue, mean(variation) | 1.35 mg/dL (0.8-2.2) |
Increase of creatinine > 20% and < 50% of baseline | 3 (27.2) |
Increase of creatinine > 50% of baseline | 3 (27.2) |
Creatinine after dengue, mean (variation) mg/dL | 1.1 (0.8-1.7) |
Creatinine 1 mo after dengue, mean (variation) mg/dL | 1.3 (0.8-1.8) |
Patient | |||||||||||
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | |
Age | 52 | 58 | 58 | 61 | 31 | 41 | 25 | 32 | 41 | 19 | 36 |
Gender | Female | Male | Male | Female | Female | Male | Male | Female | Female | Female | Female |
Pre-Tx baseline diseases | CGN | CGN+HN | FSG | DN | M G | IN | FSG | SEL | HN | BWT | DN |
Tx period until dengue | 1 yr | 10 mo | 1 mo | 4 mo and a half | 3 yr | 3 yr and 6 mo | 7 yr | 2 yr and a half | 5 yr | 7 yr and 8 mo | 9 yr |
Kind of donator | Deceased | Deceased | Deceased | Deceased | Deceased | Deceased | Deceased | Alive | Deceased | Alive | Deceased |
Induction | Thymoglobulin + methyl-prednisolone | Basiliximab + methyl-prednisolone | Thymoglobulin + methyl-prednisolone | Thymoglobulin + methyl-prednisolone | Thymoglobulin + methyl-prednisolone | Basiliximab + methyl-prednisolone | Methyl-prednisolone | Basiliximab + methyl-prednisolone | Methyl-prednisolone | Methyl-prednisolone | Methyl-prednisolone |
IMS drugs on use (during dengue period) | T + M + P | P + C + A | T + M + P | T + M | T + M + P | P + C + A | T + M + P | T + M + P | T + M + P | P + A + S | C |
Dengue symptoms | Fever, myalgia, headache | Fever, myalgia | Fever, myalgia, abdominal pain, bleedings (enter-orrhagia) | Fever, myalgia, headache | Fever, headache, abdominal pain | Fever, myalgia | Fever, myalgia, headache, hypotension, postural hypotension | Fever, myalgia, headache, vomiting, abdominal pain | Fever, myalgia, hypotension, postural hypotension | Fever, myalgia, headache | Fever, myalgia, vomiting |
Bleeding | No | No | Yes | No | No | No | Yes | No | Yes | No | No |
Dengue diagnosis | IgM+ | IgM+ | IgM+ | IgM+ | IgM+ | IgM+ | IgM+ | IgM+ and serum PCR | IgM+ | IgM+ | IgM+ |
Hemoconcentration | Yes | No | No | No | No | Yes | Yes | No | Yes | No | No |
Pleural effusions | Yes | No | No | No | No | No | No | No | Yes | No | No |
Hospitalization time | 3 d | None | 15 d | 8 d | 13 d | None | 1 mo and a half | 4 d | 20 d (ICU) | 10 d | 10 d |
Evolution | Symptom resolution in 3 d | Symptom resolution in 20 d | Symptom resolution in 15 d | Symptom resolution in 8 d | Symptom resolution in 5 d | Symptom resolution in 6 d | Symptom resolution in 16 d | Symptom resolution in 2 d | Symptom resolution in 5 d | Symptom resolution in 10 d | Symptom resolution in 8 d |
Baseline creatinine before dengue | 1 | 1.1 | 2 | 1.1 | 2.2 | 0.85 | 1.4 | 1.45 | 1.6 | 1.25 | 1 |
Maximum creatinine throughout dengue | 2 | 1.2 | 2 | 1.1 | 2.2 | 1 | 10 | 1.8 | 3.3 | 2.1 | 1.4 |
Creatinine immediately after dengue | 1 | 1.175 | 1.5 | 1.1 | 1.75 | 0.85 | 1.6 | 1.55 | 1.5 | 1.5 | 1.2 |
Creatinine 1 mo after dengue | 0.9 | 1.2 | 1.7 | 0.8 | 1.7 | 0.8 | 1.8 | 1.5 | 1.8 | 1.6 | 1 |
- Citation: Fernandes PFCBC, Siqueira RA, Girão ES, Siqueira RA, Mota MU, Marques LCBF, Andrade SCA, Barroso WM, Silva SL, Rodrigues dos Santos BG, de Oliveira CMC. Dengue in renal transplant recipients: Clinical course and impact on renal function. World J Transplant 2017; 7(1): 57-63
- URL: https://www.wjgnet.com/2220-3230/full/v7/i1/57.htm
- DOI: https://dx.doi.org/10.5500/wjt.v7.i1.57